Journal Watch · Drug Discovery Today · 2026

Multidisciplinary review method for novel target identification and prioritization for neurodegenerative diseases.

This interdisciplinary platform highlights a systematic method for accelerating early-stage drug discovery efforts for complex neurological disorders.

Rosenstock TR, Ohzeki H, Kumagai S et al.Drug Discovery Today3 min readPharma relevance 50/100

DOI: 10.1016/j.drudis.2026.104671PMID: 41967762Study type: review / perspective

TL;DR

This interdisciplinary platform highlights a systematic method for accelerating early-stage drug discovery efforts for complex neurological disorders.

Key findings

  • This interdisciplinary platform highlights a systematic method for accelerating early-stage drug discovery efforts for complex neurological disorders.

What they did

Our methodology integrates data mining, bioinformatics, bioscience, and computational chemistry to generate a prioritized list of highly tractable, actionable, and disease-relevant targets, aiming to accelerate drug discovery efforts for neurological disorders. We describe a comprehensive scoring and validation strategy based on genetic association, expression, structural features, and druggability.

Full abstract (original)

Background: Target identification (Target ID) is a foundational, multi-disciplinary method for identifying novel therapeutic targets in drug discovery, including in complex neurodegenerative diseases. Here, we outline a collaborative approach to identify, assess, and prioritize first-in-class targets.

What they did: Our methodology integrates data mining, bioinformatics, bioscience, and computational chemistry to generate a prioritized list of highly tractable, actionable, and disease-relevant targets, aiming to accelerate drug discovery efforts for neurological disorders. We describe a comprehensive scoring and validation strategy based on genetic association, expression, structural features, and druggability.

Results & conclusions: This interdisciplinary platform highlights a systematic method for accelerating early-stage drug discovery efforts for complex neurological disorders.

Abstract © the authors / Drug Discovery Today (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.drudis.2026.104671 · PubMed 41967762.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Drug Discovery Today for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Drug Discovery Today study find?

This interdisciplinary platform highlights a systematic method for accelerating early-stage drug discovery efforts for complex neurological disorders.

What type of study is this?

It is a review / perspective, published in Drug Discovery Today in 2026. Our methodology integrates data mining, bioinformatics, bioscience, and computational chemistry to generate a prioritized list of highly tractable, actionable, and disease-relevant targets, aiming to accelerate drug discovery efforts for neurological disorders.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.drudis.2026.104671. PubMed ID: 41967762. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Rosenstock TR, Ohzeki H, Kumagai S et al.. Multidisciplinary review method for novel target identification and prioritization for neurodegenerative diseases.. Drug Discovery Today (2026). DOI: 10.1016/j.drudis.2026.104671.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/multidisciplinary-review-method-for-novel-target-identification-and-prio-104671/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides